Explore insights by topic
All insights 2
Article Drug pipeline
The End of “Undruggable?”: Why RASolute-302 May Mark the Beginning of the Pan-RAS Era
The phase 3 RASolute-302 trial marks a potential turning point in oncology, demonstrating that pan-RAS inhibition with daraxonrasib may significantly improve survival in metastatic pancreatic cancer.…
Read the article
Article Cost and utilization
The New Cancer Curveball: Why Rising Rates Among Working Adults Could Hit Your Wallet Too
Health insurance premiums are projected to see their largest increase in 15 years — and rising cancer rates among working-age adults are partly to blame. Here’s…
Read the article